A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SB-656933 Following 14 Days Repeat Dosing in Healthy Male Smokers.
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Elubrixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 25 Feb 2008 New trial record.